AN CD38 UND PD-L1 BINDENDE MOLEKÜLE

European patent · EP3433273 · In force

Register entry

Publication number
EP3433273
Application number
EP17713672
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 27, 2017
Published
Jan 30, 2019
Granted
Dec 29, 2021
Protection ends at the latest
Mar 26, 2037
Next annual fee due
Mar 31, 2027
IPC classes
C07K 16/28 (2006.01)
A61K 39/00 (2006.01)
Priority
EP 16305350 25.03.2016
PCT application
PCT/EP2017/057220 27.03.2017
PCT publication
WO2017/162890 28.09.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  4. May 9, 2023

    Address changed

    Representative
    Valipat S.A., c/o BOVARD SA Neuchâtel, Rue des Noyers 11, 2000 Neuchâtel → VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 09.05.2023

  5. Apr 1, 2023

    Change

    Published in Swissreg on 01.04.2023

  6. Nov 9, 2022

    Change

    Published in Swissreg on 09.11.2022

  7. Feb 3, 2022

    Agent entered

    Representative
    Valipat S.A., c/o BOVARD SA Neuchâtel, Rue des Noyers 11, 2000 Neuchâtel

    Published in Swissreg on 03.02.2022

  8. Dec 29, 2021

    Granted

    Published in Swissreg on 29.12.2021

Parties

Holder

Biomunex Pharmaceuticals

113 rue de la Tour, 75116 Paris, FR

Agent

VALIPAT

c/o BOVARD LTD Optingenstrasse 16, 3013 Bern

Inventor

ZHUKOVSKY, Eugene

75016 Paris, FR

LEGER, Olivier

74800 Saint Sixt, FR

MORSE, Richard J.

75016 Paris, FR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.